top of page

2022 Externship Programs

In 2022, the Yale Biotech Club launched two externship programs with Allyx Therapeutics and Cellinfinity Bio. The YBC externship programs aim to provide students with short-term, fast-paced opportunities to gain valuable hands-on experience in different careers.



Allyx Therapeutics is a clinical-stage start-up company spun out of Professor Strittmatter’s laboratory at Yale. The goal is to develop disease-modifying therapies for neurodegenerative diseases by treating the underlying cause of synapse loss and dysfunction. Through workshops, literature reviews, and cross-team collaboration, students learned how Allyx can expand into other neurodegenerative indications and build research programs beyond Alzheimer’s disease. 

Cellinfinity Bio is revolutionizing cell therapy by developing proprietary, next-generation technologies. The company pipeline consists of clinically engineered T cells, NK cells and other immune cells that have potent activity against multiple malignancies including solid tumors. Through this externship, students learned about company operations and strategy,  bioinformatics, and IP landscape analysis.

Screen Shot 2021-08-17 at 10.43.22 AM.png

Meet the Planning Team

IMG_0014 - Milind Singh.jpeg
Milind Singh,
Program Director
Yale-Biotech-Club (3).jpg
Shengyan Jin,
Program Manager
Photo_ZY - Zhongyu
Zhongyu Yuan,
Program Director
Yale-Biotech-Club (3).jpg
Judy Chen,
Program Manager
JDow Headshot - Jonathan Dow.jpeg
Jonathan Dow,
Program director
Yiting Xu - Yiting Xu.png
Yiting Xu,
Program Director
Yale-Biotech-Club (3).jpg
Ziad Hassan,
Program Manager
bottom of page